Clozapine Levels, Clinical Response, and Side Effects

氯氮平水平、临床反应和副作用

• 批准号: 292352
• 负责人: Remington Gary
• 金额: $ 32.25万
• 依托单位: Centre for Addiction and Mental Health (Toronto)
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2013
• 资助国家: 加拿大
• 起止时间: 2013-09-01 至 2017-09-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=292352&lang=en
• 关键词: Clozapine; Clozapine Levels; Clozapine Response; Clozapine Side Effects; Schizophrenia; Therapeutic Drug Monitoring; Treatment Resistant Schizophrenia

It is estimated that approximately one third of individuals with schizophrenia are 'treatment resistant', meaning that they show a poor response to the drugs (antipsychotics) available. However, there is one antipsychotic, clozapine, that seems to work in

据估计，大约三分之一的精神分裂症患者是“治疗抵抗”，这意味着他们对现有药物（抗精神病药物）的反应很差。然而，有一种抗精神病药，氯氮平，似乎在